VVOTERS

METHOD MIGRATION FROM UPLC TECHNOLOGY TO PREPARATIVE HPLC

Diane M. Diehl, Fang Xia, Jie Y. Cavanaugh, Kenneth J. Fountain, Jo-Ann M. Jablonski, Thomas E. Wheat

WATERS CORPORATION, Milford, MA USA

INTRODUCTION

UltraPerformance LC[®] (UPLC[®] Technology) has been widely accepted due to the improvements over HPLC in sensitivity, resolution, and speed. For applications such as impurity and metabolite profiling, methods developed with UPLC Technology must be transferred to the preparative scale in order to isolate and purify desired compounds for further characterization.

Therefore, a systematic approach for transferring UPLC separations to the preparative scale was developed. Key parameters to consider include: column chemistry, particle size and dimension, injection volume, separation temperature, mobile phase composition, flow rate, gradient slope, cycle time, detector sensitivity, injector design, and system volume (both UPLC and preparative HPLC). Step-by-step calculations are included for a better understanding of evaluating method transfer validity. In addition, optimization of the preparative HPLC separation for impurity isolation and purification is discussed.

EXPERIMENTAL CONDITIONS CLICK ON PART NUMBERS FOR MORE INFORMATION

UPLC Conditions

Instrument:	Waters ACQUITY UPLC [®] System with PDA			
Column:	ACQUITY UPLC BEH C ₁₈ , 2.1 x 50 mm, 1.7 μm			
	Part Number: <u>186002350</u>			
Mobile phase A:	10 mM NH ₄ HCO ₃ , pH 10.0			
Mobile phase B:	ACN/100 mM NH ₄ HCO ₃ , pH 10.0 (90/10)			
Flow rate:	1.0 mL/min			
Inj. Volume:	2 μL (partial loop; 5 μL sample loop)			
Sample:	38 μ g/mL total concentration in DMSO			
	(compounds shown in Figure 1)			
Column temp.:	Ambient			
Gradient:	5-95% B in 2 min, hold at 95% for 1 min,			
	reset, 5 min total run time			
Strong wash solvent:	90/10 ACN/H ₂ 0			
Weak wash solvent:	5/95 ACN/H ₂ 0			
Detection:	245 nm			
Sampling rate:	20 pts/sec			





[APPLICATION NOTE]

MAINTAINING RESOLUTION IN SCALE-UP

To maintain resolution, the ratio of column length (L) to particle size (dp) must remain constant. For example, the following columns have the same resolution:

50 mm (L)/1.7 μ m (dp) = 29,412

100 mm (L)/ $3.5 \mu \text{m}$ (dp) = 28,571

150 mm (L)/5 μm (dp) = 30,000

Based on this calculation, an XBridge^T Prep C₁₈ OBD^T, 19 x 150 mm, 5 µm column was chosen for scaling up the UPLC separation shown in Figure 2A. Since the same base particle is used for both XBridge and ACQUITY UPLC BEH columns, selectivity remains constant.

SCALING INJECTION VOLUME

$$\operatorname{Vol}_{\operatorname{PREP}} = \operatorname{Vol}_{\operatorname{UPLC}} \bullet \frac{\operatorname{D}^{2}_{\operatorname{PREP}}}{\operatorname{D}^{2}_{\operatorname{UPLC}}} \bullet \frac{\operatorname{L}_{\operatorname{PREP}}}{\operatorname{L}_{\operatorname{UPLC}}},$$

where Vol is the injection volume (μ L), D is the inner diameter of the column (mm), and L is the column length (mm). A 2 μ L injection on a 2.1 x 50 mm UPLC column corresponds to a 491 μ L injection on a 19 x 150 mm preparative column.

SCALING FLOW RATE

Geometic Scale-up

Based on column dimensions, the following equation is used to geometrically scale flow rate:

$$\mathsf{F}_{\mathsf{PREP}} = \mathsf{F}_{\mathsf{UPLC}} \bullet \frac{\mathsf{D}^2_{\mathsf{PREP}}}{\mathsf{D}^2_{\mathsf{UPLC}}},$$

where F is flow rate (mL/min). A 1.0 mL/min flow rate on a 2.1 mm i.d. column equates to an 81.9 mL/min flow rate on a 19 mm i.d. column. However, this flow rate is not reasonable for the 19 x 150 mm column dimension. Typical flow rates are in the 15-40 mL/min range

Since optimal flow rate is inversely proportional to particle size (dp), we can use the following equation to calculate the proper flow rate for the preparative column:

$$F_{PREP,opt} = F_{UPLC,opt} \bullet \frac{D_{PREP}^2}{D_{UPLC}^2} \bullet \frac{d_{P_{UPLC}}}{d_{P_{OPDC}}}$$

Using this equation, a 1.0 mL/min flow rate on a 2.1 mm i.d., 1.7 μ m UPLC column corresponds to a 27.8 mL/min flow rate on a 19 mm i.d., 5 μ m preparative column.

CALCULATING GRADIENT OFFSET TIME

The differences in dwell volume (also called system volume) between the ACQUITY UPLC system and preparative HPLC system will result in retention time shifts. The dwell volume of any system is defined as the volume between the pump and the column inlet. In order to properly scale from UPLC to the preparative scale, one must compensate for this dwell volume by introducing an initial hold time at the start of the preparative gradient (1).

Dwell Volume of ACQUITY UPLC System:

Measured dwell volume = $0.105 \text{ mL} (5 \mu \text{L sample loop})$ Volume of a 2.1 x 50 mm UPLC column = 0.173 mL Dwell volume (mL)/column volume (mL) = column volumes 0.105 mL/0.173 mL = 0.607 column volumes (c.v.)

The ACQUITY UPLC system used for this work has a dwell volume of 0.607 c.v.

Dwell volume of preparative HPLC system:

Measured dwell volume = 2.6 mL (1 mL sample loop) Volume of 19 x 150 mm preparative column = 42.53 mL2.6 mL/42.53 mL = 0.061 c.v.

The preparative HPLC system has a dwell volume of 0.061 c.v.

Dwell volume differences between two systems:

0.607 c.v. - 0.061 c.v. = 0.546 c.v. $0.546 \text{ c.v.} \times 42.53 \text{ mL}$ (c.v. of prep column) = 23.22 mL This is also the initial hold volume

Calculating initial hold time:

Hold time = Initial hold volume/flow rate

- = 23.22/27.8 mL/min
- = 0.83 minutes

This initial hold is programmed before the start of the preparative gradient to compensate for the volume difference between the UPLC and preparative HPLC systems.

CALCULATING THE GRADIENT TABLE

In order to properly scale from UPLC to preparative HPLC, column volumes must remain constant for each segment of the gradient.

UPLC Gradient Table

UPLC Column 2.1 x 50 mm,	Steps	Time (min)	Flow Rate (mL/min)	% A	%В	Segment Duration Time (min)	Segment Duration (c.v.)
	Initial Hold	0	1.0	95	5	0	0
		2	1.0	5	95	2	11.56
1.7 µm		3	1.0	5	95	1	5.78
		3.1	1.0	95	5	0.1	0.58
		5.0	1.0	95	5	1.9	10.98

Below is an example of how to calculate the duration of a gradient segment in column volumes:

Segment duration = segment duration in min x flow rate

column volume

$$\label{eq:segment_duration} \begin{split} \text{Segment duration} = & \frac{2 \ \text{min} \ \text{x} \ 1.0 \ \text{mL}/\text{min}}{0.173 \ \text{mL}} = & 11.56 \ \text{c.v.} \end{split}$$

To preserve the separation profile, the UPLC segment durations need to be maintained in the preparative HPLC gradient table.

Preparative HPLC Gradient Table

Gradient segment volume = duration in c.v. x column volume

Gradient segment volume = $11.56 \text{ c.v. } \times 42.53 \text{ mL} = 491.65 \text{ mL}$

Gradient segment time = segment volume/flow rate

Gradient segment time = 491.65 mL/27.8 mL/min = 17.67 min

Since the first gradient segment is 17.67 min long, and the initial hold time is 0.83 min, the ending time for the segment is 0.83 min + 17.67 min, or 18.50 min.

Using these same calculations for gradient segment volume and gradient segment time for the remaining segments in the UPLC gradient table, the gradient table for the preparative HPLC run can be completed. The scaling comparison between UPLC and preparative HPLC can be found in Figure 2.

Prep LC 19 x 150 mm, 5 μm	Steps	Time (min)	Flow Rate (mL/min)	% A	% B	Segment Duration Time (min)	Segment Duration (c.v.)
	Initial Hold	0.83	27.8	95	5	0	0
		18.50	27.8	5	95	17.67	11.56
		27.33	27.8	5	95	8.83	5.78
		28.21	27.8	95	5	0.88	0.58
		45.00	27.8	95	5	16.78	10.98

Preparative HPLC Conditions

System:	AutoPurification [™] system with 996 PDA			
	AutoPurification flowcell			
Column:	XBridge Prep C ₁₈ OBD, 19 x 150 mm, 5 µm			
	Part Number: <u>186002979</u>			
Mobile phase A:	10 mM NH ₄ HCO ₃ , pH 10.0			
Mobile phase B:	ACN/100 mM NH ₄ HCO ₃ , pH 10.0 (90/10)			
Flow rate:	27.8 mL/min			
Inj. Volume:	491 µL			
Sample:	$38\mu\text{g/mL}$ total concentration in DMSO			
Column temp.:	Ambient			
Gradient:	shown above			
Detection:	245 nm			
Sampling rate:	l pt/sec			

[APPLICATION NOTE]

Figure 2. Directly scaled separation of 5 basic compounds. (A) Initial UPLC run, (B) XBridge Prep C_{18} OBD column, 19 x 150 mm. Compounds: (1) labetalol, (2) quinine, (3) diltiazem, (4) verapamil, and (5) amitriptyline.



SCALING TO A SHORTER PREPARATIVE COLUMN

It is clear from Figure 2 that the scaling procedure was successful for transferring the UPLC separation of 5 standard basic compounds. Relative retention times and resolution between peaks was almost identical on both the UPLC column and preparative HPLC column.

However, total cycle time of the preparative separation can be optimized by using a shorter length column. This will also help to decrease mobile phase usage, backpressure, and final volume of collected fractions. By slightly increasing the flow rate from 27.8 to 30.0 mL/min, and using a 50 mm length column instead of a 150 mm length column, the preparative HPLC separation can be optimized for faster cycle times. Using the calculations described previously for initial hold time and gradient segment duration, a new gradient table can be formulated:

	Steps	Time (min)	Flow Rate (mL/min)	% A	% B	Segment Duration Time (min)	Segment Duration (c.v.)
Prep LC	Initial Hold	0.20	30	95	5	0	0
19 x 50 mm, 5 μm		5.66	30	5	95	5.46	11.56
		8.39	30	5	95	2.73	5.78
		8.66	30	95	5	0.27	0.58
		13.84	30	95	5	5.18	10.98

Figure 3. Maximum loading of 5 basic compounds with minimum cycle time. (A) Initial UPLC run, (B) 18.66 μ g load on an XBridge Prep C₁₈ OBD column, 19 x 50 mm, (C) 190 mg load on an XBridge Prep C₁₈ OBD column, 19 x 50 mm. Compounds: (1) labetalol, (2) quinine, (3) diltiazem, (4) verapamil, and (5) amitriptyline.



Figure 3 shows the separation of the standard mixture on UPLC (A) and on the 19×50 mm preparative column (B). Again, resolution and relative retention times are similar, as in Figure 2. However, cycle time on the 50 mm length column is now 14 minutes instead of 45 minutes (150 mm long column). Figure 4C shows what the overloaded chromatogram looks like for purification of 190 mg of total material on the 50 mm length preparative column. The maximum amount of material that could be loaded onto the 19 x 50 mm column was determined in a separate loading study (data not shown).

IMPURITY/DEGREDANT SEPARATION FROM API

Separation and subsequent scale-up purification of very complex mixtures is more challenging. Crucial parameters in the success of these applications include: (a) maintaining baseline resolution between closely eluting peaks under high mass loading conditions, (b) effectively scaling up the separation so that it is identical to the UPLC separation, and (c) collecting and re-analyzing each fraction to ensure high purity of isolated components.

Ranitidine, the active pharmaceutical ingredient (API) in Zantac[®], was degraded by heating a 2 mg/mL standard solution in MeOH/H₂O (20/80) for 48 hours at 85 °C. A UPLC method was developed to separate all impurities and degradants from the API (Figure 4A). The method was then transferred to a 19 x 150 mm, 5 μ m XBridge Prep C₁₈ OBD column to demonstrate that the separation is linearly scaled between both instrument platforms (Figure 4B). Resolution of the highlighted degradant from the API was maintained at the preparative scale, but total cycle time was almost 90 minutes.

To optimize the cycle time, a focused gradient was developed on the 19×150 mm column (1,2). Figure 4C shows the optimized separation of the highlighted degradant from the API. This particular peak was collected, re-analyzed, and shown to have a purity > 99% by UV.

Focused gradients not only provide better resolution between closely eluting peaks, but also help to reduce overall cycle time.

Figure 4. Isolation and purification of a degradant of ranitidine. (A) Initial UPLC run, (B) Directly scaled separation on an XBridge Prep C_{18} OBD column, 19 x 150 mm, (C) Focused gradient separation for impurity isolation on an XBridge Prep C_{18} OBD column, 19 x 150 mm.



Conditions

Columns:	ACQUITY UPLC BEH C ₁₈ , 2.1 x 50 mm, 1.7 μ n
	Part Number: <u>186002350</u>
	XBridge Prep C ₁₈ OBD, 19 x 150 mm
	Part Number: <u>186002979</u>
Mobile phase A:	10 mM NH ₄ HCO ₃ , pH 10.0
Moble phase B:	ACN
Sample:	2 mg/mL degraded ranitidine (see text)
Column temp.:	Ambient
Detection:	235 nm
Sampling rate:	20 pt/sec (UPLC); 1 pt/sec (prep HPLC)
Dwell volume:	5.4 mL (prep system with 5 mL loop)

Gradient, injection volume, and flow rate are indicated on chromatograms.

[APPLICATION NOTE]

CONCLUSION

A systematic approach for transferring separation methods developed on UPLC Technology to preparative HPLC was presented. Key factors include adjusting the flow rate for particle size, calculating system volume differences, and scaling the gradient so that column volume is kept constant. In addition, the use of focused gradients allowed for maximum loading while minimizing total cycle time for preparative HPLC. Since XBridge Prep OBD columns are built on the same base particle as ACQUITY UPLC BEH columns, UPLC can be used for rapid method development of preparative separations. Subsequently, these methods can be easily transferred from UPLC to preparative LC systems.

REFERENCES

- Jablonski JM, Wheat TE, Diehl DM. Practical considerations in using, scaling, and evaluating preparative chromatography. Waters Application Note, in preparation, 2007.
- Cleary R, Lefebvre P, Twohig M. Scaling a separation from UPLC to purification using focused gradients. Waters Application Note, in preparation, 2007.

Austria and European Export (Central South Eastern Europe, CIS and Middle East) 43 1 877 18 07, Australia 61 2 9933 1777, Belgium 32 2 726 1000, Brazil 55 11 5094 3788, Canada 1 800 252 4752 x2205, China 86 21 6879 5888, CIS/Russia 7 095 336 7000, Czech Republic 420 2 617 1 1384 Denmark 45 46 59 8080, Finland 358 9 5659 6288, France 33 1 30 48 72 00, Germany 49 6196 400600, Hong Kong 852 29 64 1800 Hungary 36 1 350 5086, India and India Subcontinent 91 80 2837 1900, Ireland 353 1 448 1500, Italy 39 02 27 421 1, Japan 81 3 3471 7191 Korea 82 2 820 2700, Mexico 52 55 5200 1860, The Netherlands 31 76 508 7200, Norway 47 6 384 60 50, Poland 48 22 833 4400 Puerto Rico 1 787 747 8445, Singapore 65 6273 1221, Spain 34 93 600 9300, Sweden 46 8 555 11 500, Switzerland 41 56 676 70 00 Taiwan 886 2 2543 1898, United Kingdom 44 208 238 6100

All other countries: Waters Corporation U.S.A. 1 508 478 2000/1 800 252 4752





THE SCIENCE OF WHAT'S POSSIBLE.™

© 2007 Waters Corporation. Waters, The Science of What's Possible, UltraPerformance LC, UPLC, ACQUITY UPLC, XBridge, OBD, AutoPurification, and The Science of What's Possible are trademarks of Waters Corporation. Zantac is a registered trademark of GlaxoSmithKline.

October 2007 IH-PDF 720002375EN

Waters Corporation

34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com